We found an increase in iNKT and CD69+iNKT cells in NAFLD patients with significant liver fibrosis, suggesting that CD69+iNKT cells could be a biomarker of liver fibrosis progression in NAFLD. The gene discussed is CD69; the disease is metabolic dysfunction-associated steatotic liver disease.